EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics

Dongliang Wei, Yilan Sun, Jing Han, Jiannan Liu

Seminars in Cancer Biology · 2026-01 · 118 · 62-73

DOI: 10.1016/j.semcancer.2025.12.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2026-01. Verfasst von Dongliang Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and maxillofacial Head and neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shan…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Precision Medicine, Microbiota. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The microbiota has emerged as a pivotal modulator of cancer immunotherapy, offering novel insights into the efficacy and toxicity of immune checkpoint inhibitors (ICIs). Recent evidence highlights that microbial communities and their metabolites dynamically regulate host immunity by priming dendritic cells, enhancing T-cell infiltration, and reprogramming the tumor microenvironment. Microbiome dysbiosis is implicated in immune-related adverse events (irAEs), underscoring its dual role in therapeutic outcomes. Leveraging these findings, precision microbiome interventions, including fecal microbiota transplantation, engineered probiotics, and dietary modulation, which demonstrate potential to enhance ICIs responsiveness and mitigate irAEs in preclinical and early-phase clinical studies. However, translating these strategies into clinical practice requires rigorous validation through multicenter trials to establish safety, efficacy, and standardized protocols. This review synthesizes current knowledge on the microbiome-immune-oncology axis, with a focus on mechanistic underpinnings, translational challenges, and innovative therapeutic strategies. By integrating microbiome profiling with patient-specific factors, proposing a roadmap for personalized immunotherapy, aligning with the emerging paradigm of precision oncology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapyPrecision MedicineMicrobiotaGastrointestinal MicrobiomeHumansAnimalsTumor MicroenvironmentImmune Checkpoint InhibitorsDysbiosis

Stichwörter der Autor:innen

Cancer immunotherapyCancer microbiomeGut microbiotaMicrobial metabolitesOral microbiota

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oral and maxillofacial Head and neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, PR China; College of Stomatology, Shanghai Jiao Tong Univ…

Förderung

  • National Natural Science Foundation of China
  • Shanghai Jiao Tong University

Zitieren

APA

Wei, D., Sun, Y., Han, J., & Liu, J. (2026). Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics. Seminars in Cancer Biology, 118, 62-73. https://doi.org/10.1016/j.semcancer.2025.12.002

Vancouver

Wei D, Sun Y, Han J, Liu J. Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics. Seminars in Cancer Biology. 2026;118:62-73. doi:10.1016/j.semcancer.2025.12.002

BibTeX
@article{Wei2026,
  author = {Wei, Dongliang and Sun, Yilan and Han, Jing and Liu, Jiannan},
  title = {Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics},
  journal = {Seminars in Cancer Biology},
  year = {2026},
  volume = {118},
  pages = {62--73},
  doi = {10.1016/j.semcancer.2025.12.002}
}
Kostenlos starten →